154 related articles for article (PubMed ID: 17766997)
21. Role of Agents other than Tumor Necrosis Factor Blockers in the Treatment of Psoriatic Arthritis.
Atzeni F; Costa L; Caso F; Scarpa R; Sarzi-Puttini P
J Rheumatol Suppl; 2015 Nov; 93():79-81. PubMed ID: 26523064
[TBL] [Abstract][Full Text] [Related]
22. Amyotrophic lateral sclerosis developing during adalimumab therapy for psoriatic arthritis.
Bougea A; Anagnostou E; Stamboulis E; Kararizou E
Rev Neurol (Paris); 2014 Mar; 170(3):228-9. PubMed ID: 24656415
[No Abstract] [Full Text] [Related]
23. Double Infection in a Patient with Psoriatic Arthritis Under TNF-alpha Blockers Therapy: A Case Report.
Caroleo B; Migliore A; Cione E; Zampogna S; Perticone F; Sarro G; Gallelli L
Curr Drug Saf; 2019; 14(2):147-150. PubMed ID: 30648521
[TBL] [Abstract][Full Text] [Related]
24. Paradoxical psoriatic arthritis in a patient with rheumatoid arthritis treated by TNFα blocker.
Villani AP; Weiler L; Jullien D; Chapurlat R; Confavreux C
Joint Bone Spine; 2014 Oct; 81(5):455-6. PubMed ID: 24561024
[No Abstract] [Full Text] [Related]
25. Malignancy and mortality rates in patients with severe psoriatic arthritis requiring tumour-necrosis factor alpha inhibition: results from the British Society for Rheumatology Biologics Register.
Fagerli KM; Kearsley-Fleet L; Mercer LK; Watson K; Packham J; Symmons DPM; Hyrich KL
Rheumatology (Oxford); 2019 Jan; 58(1):80-85. PubMed ID: 30137485
[TBL] [Abstract][Full Text] [Related]
26. Successful rechallenge with anti-tumor necrosis factor alpha for psoriatic arthritis after development of demyelinating nervous system disease during initial treatment: comment on the article by Mohan et al.
Cisternas M; Gutiérrez M; Jacobelli S
Arthritis Rheum; 2002 Nov; 46(11):3107-8; author reply 3108-9. PubMed ID: 12428265
[No Abstract] [Full Text] [Related]
27. Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors.
Mease PJ
Ann Rheum Dis; 2002 Apr; 61(4):298-304. PubMed ID: 11874829
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy.
Rudwaleit M; Van den Bosch F; Kron M; Kary S; Kupper H
Arthritis Res Ther; 2010; 12(3):R117. PubMed ID: 20553600
[TBL] [Abstract][Full Text] [Related]
29. Malignancies developing in obese patients with psoriasis while on antitumour necrosis factor-α therapies: a case series.
Sadlier M; Lally A; Kirby B
Br J Dermatol; 2012 Oct; 167(4):937-8. PubMed ID: 22428935
[No Abstract] [Full Text] [Related]
30. Biological agents in psoriatic arthritis.
Kocijan R; Muschitz C; Rech J
Wien Med Wochenschr; 2015 Jan; 165(1-2):36-9. PubMed ID: 25205184
[TBL] [Abstract][Full Text] [Related]
31. Anti-tumour necrosis factor-induced cutaneous leishmaniasis in patient with psoriatic arthritis and uveitis.
Hernandez Bel L; Hernández Garfella ML; Chiarri Toumit C; Valenzuela Oñate C
Arch Soc Esp Oftalmol (Engl Ed); 2018 Dec; 93(12):621-622. PubMed ID: 30100239
[No Abstract] [Full Text] [Related]
32. Four cases of Japanese patients with psoriatic arthritis in whom effective treatments by anti-tumor necrosis factor-α drugs were evaluated by magnetic resonance imaging together with improvement of skin lesions.
Yonenaga T; Saeki H; Nakagawa H; Fukuchi O; Umezawa Y; Hayashi M; Ito T; Yanaba K; Tojyo S; Fukuda K
J Dermatol; 2015 Jan; 42(1):49-55. PubMed ID: 25425546
[TBL] [Abstract][Full Text] [Related]
33. Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs.
Perrotta FM; Marchesoni A; Lubrano E
J Rheumatol; 2016 Feb; 43(2):350-5. PubMed ID: 26669925
[TBL] [Abstract][Full Text] [Related]
34. Vasculitis, vitiligo, thyroiditis, and altered hormone levels after anti-tumor necrosis factor therapy.
Lahita RG; Vernace MA
J Rheumatol; 2011 Mar; 38(3):579-80. PubMed ID: 21362795
[No Abstract] [Full Text] [Related]
35. [Treatment of psoriatic arthritis with TNF alpha-antagonists].
Antoni C; Manger B
Z Rheumatol; 2003 Jun; 62(3):235-9. PubMed ID: 12827399
[TBL] [Abstract][Full Text] [Related]
36. Therapy: Ustekinumab after anti-TNF failure: a step closer to the PSUMMIT of psoriatic arthritis therapy?
Onuora S
Nat Rev Rheumatol; 2014 Mar; 10(3):125. PubMed ID: 24535545
[No Abstract] [Full Text] [Related]
37. Hospitalizations of patients treated with anti-tumor necrosis factor-α agents -- a retrospective cohort analysis.
Zisman D; Haddad A; Hashoul S; Laor A; Bitterman H; Rosner I; Eder L; Balbir-Gurman A; Mader R; Milman U
J Rheumatol; 2013 Jan; 40(1):16-22. PubMed ID: 23070992
[TBL] [Abstract][Full Text] [Related]
38. Rheumatoid arthritis, TNF inhibitors, and non-melanoma skin cancer.
Assassi S
BMJ; 2016 Jan; 352():i472. PubMed ID: 26822198
[No Abstract] [Full Text] [Related]
39. Multiple haemangiomas in a psoriatic arthritis patient treated with cyclosporine.
Flicinski J; Brzosko M; Olewniczak S
Acta Derm Venereol; 2006; 86(3):271-2. PubMed ID: 16710599
[No Abstract] [Full Text] [Related]
40. Follow-up of psoriatic arthritis mutilans patients treated with anti-TNF-alpha therapy.
Pomerantz RG; Mody E; Husni ME; Qureshi AA
J Drugs Dermatol; 2009 Apr; 8(4):406-12. PubMed ID: 19363860
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
